Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of dovitinib in pediatric patients with osteosarcoma

Next Previous
X
Search
Trial Profile

Efficacy and safety of dovitinib in pediatric patients with osteosarcoma

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Osteosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Allarity Therapeutics

    • Most Recent Events

    • 02 Oct 2023 According to an Oncoheroes Biosciences media release, U.S. Food and Drug Administration (FDA) has allowed the Boston-based biotech to begin this clinical trial of dovitinib in pediatric patients with osteosarcoma.
    • 02 Oct 2023 According to an Oncoheroes Biosciences media release, company has submitted Investigational New Drug (IND) application to the FDA In August seeking permission to initiate clinical trial.After FDAs thorough review and evaluation, Oncoheroes reported that IND have received the green light from the FDA to move forward.
    • 15 Mar 2021 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top